LivingGLP1
Study S002763

A Study Investigating Safety, Tolerability and Efficacy of UBT251 in Participants Living With Overweight or Obesity

ClinicalTrials.gov record

Registration

Registration
NCT07395687
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE2
Masking
DOUBLE
Status
RECRUITING
Enrollment
333
Start
2026-02-02
Primary completion
2027-01-14
Lead sponsor
Novo Nordisk A/S
Conditions
Overweight; Obesity
Interventions
DRUG:UBT251; DRUG:Placebo
Results posted
FALSE
Individual participant data sharing
YES
Secondary identifiers
OTHER:U1111-1324-3831

Registered primary outcomes

  • Part A - Number of treatment emergent adverse events (TEAEs) [From baseline (week 0) to end of study (week 33)]
  • Part B - Relative change in body weight [From baseline (week 0) to end of treatment (week 28)]
  • Part C- AUC; the area under the UBT251 plasma concentration time curve [From pre-dose on Day 1 until completion of the end of study visit (Day 43)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.